Podcasts about Zinman

durée : 00:28:38 - L'Orchestre de la Tonhalle de Zurich (3/4) : 1995-2014, les années Zinman - par : Christian Merlin - Si l'émission a fait une large place à l'Orchestre de la Suisse Romande, il est temps de se pencher sur une formation plus ancienne encore, fleuron musical de la Suisse alémanique et l'un des principaux orchestres européens. Fondé en 1868, il a intégré en 1895 la magnifique Tonhalle de Zurich. - réalisé par : Marie Grout

SaaStr 790: AI at Scale: 8 Learnings from monday.com Co-Founder and Co-Ceo Eran Zinman and SaaStr CEO and Founder Jason Lemkin Join us for an inspiring conversation with monday.com co-CEO and Co-Founder Eran Zinman and SaaStr CEO and Founder Jason Lemkin. From humble beginnings at $10 million ARR in 2017 to smashing the $1 billion ARR mark in just eight years, Eran shares their journey, challenges, and strategies that have fueled their remarkable growth. Discover the importance of customer diversity, maintaining NRR and GRR levels, leveraging AI for business efficiencies, and the impact of adopting a multi-product approach. Learn how monday.com effectively manages SMB, mid-market, and enterprise customers, and gain valuable insights into the future of AI in SaaS solutions. Perfect for SaaS founders and tech enthusiasts looking for proven strategies to scale their businesses.   ----------------------   Alright everybody in SaaS, this is it.  The biggest, best, most action-packed SaaS + AI event of the year—SaaStr Annual 2025—is coming this May. Three full days. 10,000+ SaaS and AI leaders and more tactical, no-fluff content than you'll find anywhere else.   If you want to scale faster—$10M, $50M, $100M ARR and beyond—you need the right playbooks, the right connections and the right people in your corner. And SaaStr Annual is where it all happens. We'll have 100's of Legendary speakers from companies like Snowflake, HubSpot, OpenAI, Canva, and more. More networking than you can handle—meet your next investor, co-founder, or biggest deal.  A New AI Demo & Pitch Stage— with your chance to win up to $5M in funding!  So don't wait—grab your tickets now at SaaStrAnnual.com with my code jason100 to save $100 on tickets before prices go up. That's jason 100 at saastrannual.com   See you in May!    --------------------------------------------------------------------------------------------   Do you know what would make your customer service helpdesk dramatically better? Dumping it and switching to Intercom.  But, youʼre not quite ready to make that change. We get it!   Thatʼs why Fin, the worldʼs leading AI customer service agent, is now available on every helpdesk.   Fin can instantly resolve up to 80% of your tickets,  Which makes your customers happier. And you can get off the customer service rep hiring treadmill.   Fin by Intercom. Named the #1 AI Agent in G2ʼs Winter Report.      Learn more at : inter.com/saastr   --------------------------------------------------------------------------------------------

The story of Monday.com is insane, turned down by most VCs, then scaled from $6M to $120M ARR in just three years. Today the company is public with a market cap of $12BN. Joining us in the hotseat today is Monday's Co-Founder and CEO, Eran Zinman.  In Today's Episode with Eran Zinman We Discuss: 03:03 The Role of Video Games in Founders' Success 04:12 The Fail That Taught a $10BN Founder Everything 09:40 Pivoting to a $12BN Company: How, When and Advice on Pivots 14:15 Why 99% of Investors Turned Monday Down: Fundraising Lessons 17:05 Building a Performance Marketing Engine 21:25 How to Scale ACV and Move Upmarket 28:54 What Have Been the Most Effective Marketing Strategies 29:08 How Have Monday Been So Successful with Youtube Ads?  29:43 Biggest Challenges and Lessons in Channel Spend 30:50 Building a Multi-Product Strategy: The Rise of Monday CRM 34:37 Competing in the SaaS Market: Is Competition Good? 39:30 The IPO Journey: Why Then? Pros and Cons of Being Public? 42:38 How a Co-CEO Structure Works 43:55 How to Manage a Board 45:04 Quick-Fire Q&A    

Eran Zinman entered a crowded category, out-executed everyone, and scaled monday.com into a $14B public company. In my latest conversation with him, he details their unique metric tracking system (dubbed Big Brain) that allows them to do the same amount of work with ½ the people, along with their relentless focus on cash over other metrics, and the little tactics that brought significant ROI (like sending everyone—including investors—a daily SMS with yesterday's metrics).(00:00) Introduction to the Logan Bartlett Show(01:12) The Philosophy Behind Monday.com(01:29) Building a Flexible Platform(04:12) Competing in a Crowded Market(06:21) The Evolution of Monday.com(13:43) The Importance of Cash Efficiency(14:22) Big Brain: The In-House Analytics Platform(23:54) Performance Marketing Strategies(29:47) AI Integration and Future Prospects(38:51) Founder Mode and Company Philosophy(40:53) Learning from Mistakes and Adapting(43:04) Customer Success and Service Philosophy(46:53) Building a Strong Company Culture(51:10) Interviewing and Hiring Best Practices(54:49) Going Public and Investor Relations(01:03:38) Co-CEO Model and Partnership(01:08:34) Future Vision for Monday.com(01:11:07) Embracing Failure and Continuous Improvement Executive Producer: Rashad AssirProducer: Leah ClapperMixing and editing: Justin Hrabovsky Check out Unsupervised Learning, Redpoint's AI Podcast: https://www.youtube.com/@UCUl-s_Vp-Kkk_XVyDylNwLA

ALS, a nervous system disease, ruled the headlines in the summer of 2014 thanks to the viral Ice Bucket Challenge. How has our knowledge of the disorder evolved a decade later? Amyotrophic lateral sclerosis, also known as ‘Lou Gehrig's disease' (named after the iconic baseball player), is a progressive neurological disorder which breaks down a person's motor neurons. The main symptoms are muscle weakness and impaired physical function — mild, at first, but in the latter stages of the disease's progression, essential processes like breathing begin to fail. Most individuals face a life expectancy of two to five years. A small percentage live five to ten years. And an even tinier group survive beyond a decade. Most famously, renowned physicist Stephen Hawking survived more than 50 years past his diagnosis, in part due to the intensive care he was able to afford. In this episode of the ‘Your Brain On...' podcast, we discuss: • What ALS is, and how it affects the brain and the body • The onset and progression of ALS, from the earliest symptoms to the end-stage impacts • How ALS patients are diagnosed, treated, and cared for • Likely causes of ALS, including genetic predispositions and potential environmental risk factors • How new technologies are rapidly accelerating our understanding of ALS, especially in genetics Joining us for this installment of the show are two world-class experts on the disease: • Professor Ammar Al-Chalabi PhD, Professor of Neurology and Complex Disease Genetics at the Maurice Wohl Clinical Neuroscience Institute at King's College. • Merit Cudkowicz, Director of the Sean M. Healey & AMG Center for ALS at Massachusetts General Hospital. ‘Your Brain On' is hosted by neurologists, scientists and public health advocates Ayesha and Dean Sherzai. ‘Your Brain On... ALS' • SEASON 4 • EPISODE 3 ——— LINKS PROFESSOR AMMAR AL-CHALABI at King's College: https://www.kcl.ac.uk/people/ammar-al-chalabi at Motor Neurone Disease Disease Association: https://www.mndassociation.org/get-involved/cure-finders/professor-ammar-al-chalabi Project MinE: https://projectmine.com/ MERIT CUDKOWICZ at Massachusetts General Hospital: https://www.massgeneral.org/doctors/16904/merit-cudkowicz  at Harvard University: https://researchers.mgh.harvard.edu/profile/1520993/Merit-Cudkowicz ——— ANNOUNCING: NEURO WORLD RETREAT 2025 We're so excited to share something very close to our hearts, which we've been working on over the past few months: our first ever brain health retreat! You're warmly invited to join us in San Diego, California for the inaugural NEURO World Retreat 2025, taking place September 2–5, 2025 at the breathtaking Paradise Point Resort. For more information, and to book, visit: https://neuroworldretreat.com/ ——— FOLLOW US Join the NEURO Academy: NEUROacademy.com Instagram: @thebraindocs Website: TheBrainDocs.com More info and episodes: TheBrainDocs.com/Podcast ——— References: Brown, Robert H., and Ammar Al-Chalabi. "Amyotrophic lateral sclerosis." New England Journal of Medicine 377.2 (2017): 162-172. Benatar, Michael, et al. "A roadmap to ALS prevention: strategies and priorities." Journal of Neurology, Neurosurgery & Psychiatry 94.5 (2023): 399-402. Voigtlaender, Sebastian, et al. "Artificial intelligence in neurology: opportunities, challenges, and policy implications." Journal of Neurology 271.5 (2024): 2258-2273. Zinman, Lorne, and Merit Cudkowicz. "Emerging targets and treatments in amyotrophic lateral sclerosis." The Lancet Neurology 10.5 (2011): 481-490. Raghav, Yogindra, et al. "Identification of gene fusions associated with amyotrophic lateral sclerosis." Muscle & Nerve 69.4 (2024): 477-489. Su, Feng-Chiao, et al. "Association of environmental toxins with amyotrophic lateral sclerosis." JAMA neurology 73.7 (2016): 803-811. Talbott, Evelyn O., et al. "Case-control study of environmental toxins and risk of amyotrophic lateral sclerosis involving the national ALS registry." Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration (2024): 1-10.

durée : 01:28:38 - David Zinman, l'enthousiasme et la maîtrise - par : Aurélie Moreau - Après ses débuts avec l'Orchestre de Chambre des Pays Bas, le chef américain David Zinman a été notamment directeur musical des orchestres de Rochester, Rotterdam et Baltimore, puis de l'Orchestre de la Tonhalle de Zurich de 1995 à 2014.

Our hearts are singing and everything is groovy as this week we take the field and welcome Matt Zinman and Craig Gerard(How I Met Your Mother, Trial and Error) on to the show to talk about MAJOR LEAGUE.We wonder about whether it holds up or not, Charlie Sheen's performance and character as Wild Thing, and talk baseball movies. Patreon: http://patreon.com/PodcastlikeitsTwitter: http://twitter.com/podcastlikeitsInstagram: http://instagram.com/podcastlikeitsReddit: http://reddit.com/r/podcastlikeits Hosted on Acast. See acast.com/privacy for more information.

My guest on this episode of Decode Your Burnout is Matt Zinman. He's a renowned expert on uncommon mindset techniques that foster presence and resilience. As a passionate advocate for mood health, Matt sheds light on the forces that distract us, from past regrets to future uncertainties and the automatic negative thoughts (ANTs) that often cloud our judgment. In this episode, we dive deep into the essence of resilience and the importance of being present. We explore three pivotal mindset techniques: the power of self-kindness, the significance of earned confidence, and the role of amplified awareness. Matt also touches upon the motivations that drive us, emphasizing the joys in life that can only be experienced in the present. Join us for an enlightening discussion filled with invaluable insights and tools for personal growth.     More of Matt's uncommon mindset techniques:   1) Z-isms - Free Book: mattzinman.com   2) Z-isms podcast   3) Mindset Reset   4) Download a Copy of the Burnout Checklist: https://www.drsharongrossman.com/burnoutchecklist   5) Sign up for a FREE Breakthrough Session with Dr. Sharon: http://www.bookachatwithsharon.com   6) Take the first step to Decode Your Burnout: http://decodeyourburnout.com

In this episode of the AZREIA show, host Marcus Maloney and co-host Mike Del Prete are joined by Mark Zinman, an attorney from Zona Law Group, to discuss all things law and legislation related to landlord-tenant and real estate matters.  The episode covers issues such as tenant complaints, risk management, and creative financing options for real estate investors.  The conversation is helpful for anyone who owns and rents out property, from single-family homes to multi-family complexes.  I highly recommend giving it a listen. And as always, don't forget to subscribe to the AZREIA Show for more great content every Friday at 8 a.m. Thanks for tuning in! Key Takeaways:  [00:03:01] Landlord-friendly state or not.  [00:06:09] President's blueprint for renters' rights.  [00:08:05] Renter's rights and fair leases.  [00:13:27] Tenant's right to an attorney.  [00:13:41] Eviction and rental assistance. [00:18:53] Tenant screening is critical.  [00:19:55] Property management and liability.  [00:25:49] Protected class source of income.  [00:26:18] Discrimination against a source of income.  [00:29:15] Small landlords impacted by policies.  [00:32:24] Section 8 and Rental Contracts.  [00:36:11] Anti-manufactured home communities.  [00:39:00] Take Action and Generate Awareness. Connect with Mark Zinman at:  www.zona.law | (480) 949-1400 | mark@zona.law   ---- The Arizona Real Estate Investors Association provides its members the education, market information, support, and networking opportunities that will further the member's ability to successfully invest in Real Estate. Join AZREIA here. Is a Career in Real Estate Right For You? Take AZREIA's Real Estate Investing Entrepreneurial Self-Assessment at  

This is the Weight and Healthcare newsletter! If you like what you are reading, please consider subscribing and/or sharing!In part 1 we talked about a request that has been submitted for the World Health Organization (WHO) to add diet drugs (specifically GLP1 agonists like Novo Nordisk's Saxenda and Wegovy) to their list of “essential medicines.” We discussed who was making this request and the justification that they were using. In part 2 we took a deeper dive into the research that they used to try to support this request, and in this final installment, we will look at the research around efficacy, harm, and cost-effectiveness.First I'll offer a summary for each issue and then I'll give a breakdowns of the research that they cite.  Just a quick reminder that this request is asking the World Health Organization (WHO) to add these drugs to their list of “essential medications” globally.Before we get into the sections, I want to mention two overarching issues that are found throughout the entirety of this request and the studies that are used to support it.First, in general, a belief has been fomented (predominantly by those in the weight loss industry) that being higher-weight is so terrible then it's worth “throwing anything at the problem.” This leads to acceptance of poor, short-term, and/or incomplete data as “good enough” to foist recommendations onto higher-weight people, which means that part of weight stigma in healthcare is that higher-weight people are afforded less right to ethical, evidence-based medicine than thinner people.Second, is clinging to correlation (without any mechanism of causation) when it comes to weight, health, and health outcomes, including the abject failure to consider confounding variables. So throughout these studies “being higher-weight is associated with [health issue(s)]” stated uncritically in support of weight loss interventions. There is an utter failure to explore the idea that the reason for the outcome differences is not weight itself but, instead, exposure to weight stigma, weight cycling (which these medications actually perpetuate by their own admission,) and healthcare inequalities.  Issues with research supporting effectiveness, harms, and benefitsStudy Duration:This is the main issue. While there was one study that went up to 106 weeks, the vast majority of the studies are between 14 and 56 weeks. We know that these drugs can have significant, even life-threatening side effects (earning them the FDA's strongest warning.) 14-56 weeks is not not nearly enough time to capture the danger of long-term effects, or to capture long-term trends around weight loss/weight regain.Study PopulationMany of the studies included have small samples. Many have study populations are overwhelmingly white, which is a huge issue when making a global recommendations.Small effect and overlapMany of the studies show only a bit of weight loss (often 15lbs or less) and often there was overlap in weight lost between the treatment group and the placebo group. Even using the “ob*sity” construct that this request is based on, for many people, this amount of weight loss wouldn't even change their “class” of “ob*sity.”Failure to capture adverse eventsMuch of the research they use to support their claims of safety didn't actually capture individual adverse events or serious adverse events. Often they only captured subjects who reported leaving treatment due to side effects.Issues with research supporting cost effectivenessThe cost-effectiveness analyses they cite are based on Quality Adjusted Life Years (QALYs). This is a measurement of the effectiveness of a medical intervention to lengthen and/or improve patients' lives.The calculation for this is [Years of Life * Utility Value = #QALY]So if a treatment gives someone 3 extra years of life with a Health-Related Quality of Life (HRQL) score of 0.7, then the treatment is said to generate 2.1 [3 x 0.7] QALYs.This is a complicated and problematic concept that deserves its own post sometime in the future, but looking just at this request I think it's important to note that they are working on two main unproven assumptions:1. That being higher weight causes lower health-related quality of life and/or shorter life span (rather than any lower HRQL being related to experiences that higher-weight people have including weight stigma, weight cycling, healthcare inequalities et al.) 2. That this treatment induces weight loss and/or health benefits that increase the life span and/or health-related quality of life of those who take it.I don't believe either of these assumptions are proven by the material cited in the request to the WHO. Specifically, it's very possible that it's not living in a higher-weight body, but rather the experiences that higher-weight people are more likely to have (weight stigma, weight cycling, healthcare inequalities) that impact their HRQL.Further, the short-term efficacy data available (and Novo Nordisk's own admission about high rates of regain) fall far short of proving any assumptions about these drugs ability to actually improve or extend life. Further, the failure of the literature to adequately capture negative side effects of the drugs, both short and long-term, means that this calculation cannot be properly made.Incremental Cost-Effectiveness Ratio (ICER)ICER is how QALYs are turned into a monetary value. It is calculated by dividing the difference in total costs by the difference in the chosen measure of health outcome or effect.[(Cost of intervention A -Cost of Intervention B) / (Effectiveness of Intervention A – Effectiveness of Intervention B)]The result is a ratio of extra cost per extra unit of health effect of a more vs less expensive treatment which can then be measured in QALYs.Again, this is worthy of its own post because there are all kinds of ethical issues around things like how we value life, how we define “healthy” and the ethics of determining whether or not prolonging someone's life is “cost effective.” I'm not going to do a deep dive into that today, but I do want to note that it is a serious issue in these kinds of calculations.In this specific case, even if one was to get past the ethical issues, an accurate calculation is impossible to make on both of the measures of the equation.Cost of these drugs varies wildly between countries and sometimes within countries because, for example, Novo Nordisk is a for-profit corporation whose goal is to create as much profit as possible.  Per the WHO request letter, the monthly cost of liraglutide is $126 in Norway and $709 in the US. Semaglutide is $95 per 30 days in Turkey, but $804 per 30 days in US.When it comes to effectiveness of the treatment, again, there is virtually no long-term data. We do know that in Novo Nordisk's own studies, weight is regained rapidly and cardiometabolic benefits are lost when the drugs are discontinued and even when people stay on the drugs, weight loss levels off after about a year, at 68 weeks weight cycling begins, and at 104 weeks (when follow-up ended) weight was trending up. It's possible that these drugs are utterly ineffective over the long-term and/or that the prevalence of long-term side effects renders any treatment effects moot. We simply do not know.I do not think that this is a remotely appropriate basis from which to request that these drugs be declared globally essential by the WHO.Here are the citation breakdowns. These are not deep dives since there are enough issues with the research on a simple surface analysis.Breakdowns of evidence of comparative effectivenessEffects of liraglutide in the treatment of ob*sity: a randomised, double-blind, placebo-controlled study, Astrup et al.)This is a 20-week study funded by Novo Nordisk. It included 564 people on various doses of liraglutide and a placebo group who didn't get the drug and a group on orlistat. There were no more than 90-98 people in each group.The study explains “Participants on liraglutide lost significantly more weight than did those on placebo” by which they meant that those on the highest dose of liraglutide lose about 9.7lbs more than those on the placebo over the 20 weeks.III LEAD studiesThese are four studies that look at liraglutide in combination with other drugs for the treatment of Type 2 Diabetes that also included some information on weight changes. One was 52 weeks, the others were  26, the maximum amount of weight lost was only about 5lbs.   The first [Liraglutide, a once-daily human GLP-1 analogue, added to a sulphonylurea over 26 weeks produces greater improvements in glycaemic and weight control compared with adding rosiglitazone or placebo in subjects with Type 2 diabetes (LEAD-1 SU), Marre et al] was a study that looked at the efficacy of adding liraglutide or rosiglitazone 4 to glimiperide in subjects with Type 2 Diabetes to test effects on blood sugar and body size.The study followed 1041 adults for 26 weeks. The study found that those on .6mg of liraglutide gained 0.7kg, those on 1.2mg gained 0.3kg, and those on 1.8mg of liraglutide lost 0.2kg, while those on placebo lost 0.1kg.The second [Efficacy and safety comparison of liraglutide, glimepiride, and placebo, all in combination with metformin, in type 2 diabetes: the LEAD (liraglutide effect and action in diabetes)-2 study. Diabetes Care, 2009. 32(1): p. 84-90. Nauck, M., et al.,]looked at the efficacy of adding liraglutide to metformin therapy for those with Type 2 Diabetes. They found that over the 26-week study those on liraglutide lost 1.8 ± 0.2, 2.6 ± 0.2, and 2.8 ± 0.2 kg for 0.6, 1.2, and 1.8 mg doses. Those on placebo lost 1.5 ± 0.3kg.The third [Liraglutide versus glimepiride monotherapy for type 2 diabetes (LEAD-3 Mono): a randomised, 52-week, phase III, double-blind, parallel-treatment trial. Lancet, 2009. 373(9662): p. 473-81. Garber, A., et al.,] This was a study of the comparative effectiveness of Liraglutide versus glimepiride for type 2 diabetes, with small weight loss as an ancillary finding. Those in the liraglutide group lost an average of 2kg.The final study [Efficacy and safety of the human glucagon-like peptide-1 analog liraglutide in combination with metformin and thiazolidinedione in patients with type 2 diabetes (LEAD-4 Met+TZD), Zinman et al.]  was a 26-week study with 533 total subjects. The goal was to study the efficacy of liraglutide when added to metformin and rosiglitazone for people with type 2 diabetes. They found that those on liraglutide lost between 0.7 and 2.3kg (1.5lbs to 5.1lbs) in 26 weeks.Meta-Analyses and Systematic Review FindingsEfficacy of Liraglutide in Non-Diabetic Ob*se Adults: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. Barboza, J.J., et al., None of the included studies were more than 56 weeks and one was only 14 weeks. One had as many as 3731 subjects, but one had only 40. Some had body weight loss as a primary outcome, but some did not. Maximum doses ranged from 1.8 to 3.0mg. The mean body weight reduction was  3.35 kg (7.4lbs) but in one study there was no difference in weight loss. The maximum difference was 6.3kg (13.9lbs)They also refer to Iqbal et al which we discussed in part 2.Effects of glucagon-like peptide-1 receptor agonists on weight loss: systematic review and meta-analyses of randomised controlled trials. Vilsbøll, T., et al.The included studies are between 20 and 53 weeks long, and include some of the studies they already cited individually above. Of the 25 included studies only 3 had “ob*sity” as the main inclusion criteria, the rest were Type 2 Diabetes.The mean weight loss for those on the highest dose of the drug was between 0.2kg and 7.2kg. For those in the control group it was 2.9 kg, so there was actually overlap between the treatment and placebo groups.Summary of evidence of safety and harmsThey begin with the claim “The safety profile of GLP-1 receptor agonists is also well studied”To support this they cite: Efficacy and Safety of Liraglutide 3.0 mg in Patients with Overweight and Ob*se with or without Diabetes: A Systematic Review and Meta-Analysis, Konwar, M., et al.,This included 14 total studies, many of which the authors of the WHO request had cited individually and were included in other systematic reviews and meta-analyses above. The smallest study included 19 people, the largest included 2,487. The total number of subjects was 4,142.Their conclusion was “Liraglutide in 3.0 mg subcutaneous dose demonstrated significant weight reduction with a reasonable safety profile for patients with overweight or ob*sity regardless of diabetic status compared to placebo.”Their methodology says that they omitted studies from analysis due to “short duration.” They included studies that had a minimum of 12 weeks and a maximum of 56 weeks of follow-up.While they included 14 studies, only 11 of them actually included information about adverse events.In terms of adverse effects (AEs,) they found that the pooled estimate of nine studies in nondiabetic patients and two studies in diabetic patients revealed a significant proportion of patients experiencing the adverse events in liraglutide 3.0 mg group when compared with placebo., and the pooled estimate of the eleven studies showed that liraglutide 3.0 mg had higher risk of AEs compared to placebo.When it came to “serious adverse events” they found that there was a similar risk level between the drug and placebo groups, but remember that's for only 12 to 56 weeks, and Novo Nordisk is recommending that people take these drugs for the rest of their lives. A few months to a little over a year is not enough time to capture long-term serious adverse events.The efficacy and safety of liraglutide in the ob*se, non-diabetic individuals: a systematic review and meta-analysis. Zhang, P., et al.,This included five RCTs (which were included in various of the above systemic reviews and meta-analyses) ranging in follow-up from 14 to 56 weeks.The only adverse event information captured was the number of people who withdrew from treatment due to adverse events (which they found was similar between drug and placebo) and nausea (which was experienced more by people on the drug.)So, in addition to being short in duration, this was far from a comprehensive list of side effects. They made no attempt to capture serious adverse side effects and their short-term nature would have made this difficult anyway.Association of Pharmacological Treatments for Ob*sity With Weight Loss and Adverse Events: A Systematic Review and Meta-analysis. Khera, R., et al.This looked at weight loss and adverse events with a number of different weight loss drugs. Interestingly liraglutide did not show the highest amount of weight loss but was associated with the highest odds of adverse event–related treatment discontinuation. It should also be noted that high drop-out rates of 30-45% plagued all of the trials which the study authors admit means that “studies were considered to be at high risk of bias.“Given that those who drafted the WHO request are asking that these drugs be considered essential globally, it is disappointing that they included this study and didn't bother to mention this issue in their written request.This included 28 RCTs (most of which were included in other citations above) and only 3 that included liraglutide. They didn't capture individual adverse events, but only “Discontinuation of Therapy Due to Adverse Events.” They only evaluated a year of data so, again, while it is likely that these studies would have captured common adverse events had they bothered to try, there isn't long enough follow-up to have any information about serious (possibly life-threatening) long-term adverse events.Association of Glucagon-like Peptide 1 Analogs and Agonists Administered for Ob*sity with Weight Loss and Adverse Events: A Systematic Review and Network Meta-analysis. Vosoughi, K., et al.,This study included 64 RCTs with durations from 12 to 160 weeks, with a median of 26 weeks. As is common in these studies, the majority of the sample (74.9%) was white.Like those above, they only looked at treatment discontinuation from adverse events, they did not capture specific adverse events (common or serious.) Of the seven GLP-1 drugs they tested, liraglutide was tied with taspoglutide for the highest discontinuation of treatment due to adverse events.The study authors also note that “Risk of bias was high or unclear for random sequence generation (29.7%), allocation concealment (26.6%), and incomplete outcome data (26.6%).”Breakdowns for Comparative Cost-effectiveness StudiesFirst, the WHO request authors themselves admit that when it comes to cost-effectiveness, “the analyses have generally been performed only for high-income countries.” This is significant since they are asking the WHO to consider these drugs essential for the entire world.It's also important to understand that none of the data looks at a comparison of cost effectiveness for weight-neutral health interventions to these drugs. Without that information there is no way to calculate actual “cost effectiveness” since it's possible that weight-neutral health interventions would have greater benefits with less risk and dramatically lower cost.  NICE's guidance:  Liraglutide for managing overweight and ob*sity Technology appraisal guidance [TA664]Published: 09 December 2020.Do recall that NICE is involved in the current scandal with Novo Nordisk for influence peddling.These guidelines are created based on a submission of evidence by Novo Nordisk. The committee's understanding of “clinical need” was based on the testimony of a single “patient expert” who “explained that living with ob*sity is challenging and restrictive. There is stigma associated with being ob*se.”Once again we see a rush to blame body size for any “challenges” and “restrictions” of living in a higher-weight body, accompanied by the immediate decision that those bodies should be subjected to healthcare interventions that risk their lives and quality of life in order to be made (temporarily, by Novo and NICE's own admission) thinner.  There did not seem to be a patient expert to discuss the weight-neutral options.It was not immediately apparent if the patient expert was provided/paid by Novo Nordisk, but they certainly forwarded their narrative that simply living in a higher-weight body is a disease requiring treatment.It should be noted that while the trial Novo Nordisk submitted covered a wider range of people, they specifically submitted for this recommendation only the subgroup of that population who were diagnosed with “ob*sity,”  pre-diabetes, and a “high risk of cardiovascular disease based on risk factors such as hypertension and dyslipidaemia.”So, even if we accept this guidance as true, the WHO Essential Medicines request applies to a population much wider than this and so this fails to justify the cost-effectiveness for that population.This guidance is also based on the costs associated with obtaining the drugs through a “specialist weight management service” since an agreement is in place for Novo Nordisk to give a discount to these services.In calculating the ICER per QALY gained, the recommendations note that “Because of the uncertainties in the modelling assumptions, particularly what happens after stopping liraglutide and the calculation of long-term benefits, the committee agreed that an acceptable ICER would not be higher than £20,000 per QALY gained”Again, this recommendation is based on a trial submitted by Novo Nordisk that included 3,721 people and lasted for three years, but only 800 met the criteria for this cost-effectiveness recommendation. The trial failed to show a significant reduction in cardiovascular events. Novo's calculation of risk reduction was based on surrogate outcomes, which NICE points out “introduces uncertainty because causal inference requires direct evidence that liraglutide reduces cardiovascular events. This was not provided in the company submission because of lack of long-term evidence.”The NICE committee admits “relying on surrogates is uncertain but accepted that surrogate outcomes were the only available evidence to estimate cardiovascular benefits.”I just want to point out that another option would be to refuse to experiment on higher-weight people without appropriate evidence.These cost-effectiveness calculations are based on someone using the drug for two years, with no actual data on reduction in cardiovascular events, and with the admitted assumption that “any weight loss returned to the base weight 3 years after treatment discontinuation.” Said another way, this committee decided that it was cost effective to spend up to £20,000 per QALY for people to take a weight loss drug with significant side effects for two years, with no direct evidence of reduced cardiovascular events, and with the acknowledgment that people will be gaining all of their weight back when they stop taking it.Those who wrote the request for WHO to consider these drugs “essential” chose to characterize this as “At the chosen threshold of £20,000 per quality-adjusted life year (QALY) gained, the report concluded that liraglutide is cost-effective for the management of ob*sity.” I do not think that is an accurate characterization of the findings.The request cites “A report by the Canadian Agency for Drugs and Technologies in Health (CADTH) found that compared to standard care, the ICER for liraglutide was $196,876 per QALY gained”For the US, they cite a study that found that to achieve ICERs between $100,000 and $150,000 perQALY or evLY gained, the health-benefit price benchmark range for semaglutide was estimated as $7500 - $9800 per year, which would require a discount of 28-45% from the current US net price.They also cite “Cost-effectiveness analysis of semaglutide 2.4 mg for the treatment of adult patients with overweight and ob*sity in the United States, Kim et al.Let's take a look at their conflict of interest disclosure (emphasis mine)“Financial support for this research was provided by Novo Nordisk Inc. The study sponsor [that means Novo Nordisk] was involved in several aspects of the research, including the study design, the interpretation of data, the writing of the manuscript, and the decision to submit the manuscript for publication.Dr Kim and Ms Ramasamy are employees of Novo Nordisk Inc. Ms Kumar and Dr Burudpakdee were employees of Novo Nordisk Inc at the time this study was conducted. Dr Sullivan received research support from Novo Nordisk Inc for this study. Drs Wang, Song, Wu, Ms Xie, and Ms Sun are employees of Analysis Group, Inc, who received consultancy fees from Novo Nordisk Inc in connection with this study.”Given that, you probably won't be shocked to learn that this concluded that Novo Nordisk's drug, semaglutide, was cost-effective. The reason I bolded the text above is that this study is based on modeling – they are taking what is, by their own admission, a “new drug” and making predictions for 30 years. Everything was simulated based on trial data (you know, those trials that we've been discussing that often have horrendous methodology…) and “other relevant literature.” The construction of the modeling and the interpretation of the results was directed by the company who stands to benefit financially from the findings, and carried out by that company's employees and consultants.  Also, and I'll just quote again here since I don't think I can improve on their text “Cost-effectiveness was examined with a willingness-to-pay (WTP) threshold of $150,000 per QALY gained” I do not think that this WTP is based on a global assessment.In their (and by their I mean Novo Nordisk's) modeling they find that semaglutide was estimated to improve QALYs by 0.138 to 0.925 and incur higher costs by $3,254 to $25,086 over the 30-year time horizon vs comparators.And, again, this is without any kind of actual long-term data. I think that the best way to characterize this information is “back of the envelope calculations” at best.To sum up, I do not think that the research they cite comes anywhere close to proving that these drugs have levels of efficacy, safety, or cost-effectiveness that warrant their addition to the WHO list of essential medicines. I believe that if the WHO grants this request I think it will be an affront to medical science, it will cheapen the concept of “essential medicines,” and it will harm untold numbers of higher-weight people all over the world.Did you find this post helpful? You can subscribe for free to get future posts delivered direct to your inbox, or choose a paid subscription to support the newsletter and get special benefits! Click the Subscribe button below for details:Liked this piece? Share this piece:More research and resources:https://haeshealthsheets.com/resources/*Note on language: I use “fat” as a neutral descriptor as used by the fat activist community, I use “ob*se” and “overw*ight” to acknowledge that these are terms that were created to medicalize and pathologize fat bodies, with roots in racism and specifically anti-Blackness. Please read Sabrina Strings' Fearing the Black Body – the Racial Origins of Fat Phobia and Da'Shaun Harrison's Belly of the Beast: The Politics of Anti-Fatness as Anti-Blackness for more on this. Get full access to Weight and Healthcare at weightandhealthcare.substack.com/subscribe

This week's visiting professor is Mark Zinman, Attorney and Partner at Zona Law Group P.C. Mark joins us to discuss how to protect yourself as a landlord covering legal matters, evictions, and fair housing practices. To learn more about Zona Law Group P.C, visit: https://www.zona.law/ About the Apartment Academy: The Apartment Academy podcast is hosted by Leonardo247 founder, CEO, and Professor of Property, Daniel Cunningham. Each 20 to 30 minute episode features an insightful and educational conversation with a leader in the multifamily industry. Check out all the episodes and subscribe to get the latest episodes as they release here: https://lnkd.in/gkajWmFS

This week, Hesh Zinman, Commissioner, Pennsylvania Governor's Commission on LGBTQ+ Affairs, co-chair of the Aging Workgroup and founder and former chair of the LGBT Elder Initiative, discusses issues of interest to the aging LGBTQ+ community. [Read more...] The post Seekers of Meaning 1/27/2023: Hesh Zinman, LGBTQ+ Activist, on Elder Issues facing the LGBTQ+ Community appeared first on Jewish Sacred Aging.

Air date: January 12, 2023.Moderated by Mad Pinney, Artistic Coordinator at Art BlocksGuests:LoVid - Artistic duo behind Tide Predictor, part of the Art Blocks Curated collectionBenton C. Bainbridge - Artist, collector, educator, FEED and Lonely Rocks founderGregory Zinman - Curator, Professor in the School of Literature, Media, and Communication at Georgia TechDebora Bernagozzi - Artist, Executive Director and Co-founder of Signal Culture. Join us on Discord: https://t.co/NyvH1S1yvMFollow on Twitter: https://twitter.com/artblocks_io

Happiness Solved with Sandee Sgarlata. In this episode, Sandee interviews Matt Zinman. Matt began his career in brand marketing and communication management working for some of Philadelphia's most prominent agencies where he assisted nearly 100 companies, including through his own firm, Z Communication, Inc., which he started in 2002. He earned his B.A. in Journalism with a minor in film and broadcast media from Temple University in 1989. He and Erica reside near Philadelphia with their savvy teenagers, Jake and Greta. Connect with Matt: https://mattzinman.com/ Connect with Sandee www.sandeesgarlata.com Podcast: www.happinesssolved.com www.facebook.com/coachsandeesgarlata www.twitter.com/sandeesgarlata www.instagram.com/coachsandeesgarlata

Jeff Goldberg interviews Matt Zinman, CEO of The Internship Institute. He is also the host of “Insights to Live By,” a podcast. He is also the author of the highly-acclaimed book, Z-isms: Insights to Live By.Know more about Matthttps://mattzinman.com/Know more about Jeffhttps://jgsalespro.com/Connect with Jeff on LinkedIn: https://www.linkedin.com/in/jeffgoldbergsalescoach/

Our anchors begin today's show breaking down the recent slump in mega-cap stocks with CNBC's Dom Chu, and Bank of America Head of U.S. Equity and Quantitative Strategy Savita Subramanian shares her thoughts on opportunities in tech stocks that sunk during the latest correction. Then, RBC Capital Markets analyst Brad Erickson weighs in on privacy concerns surrounding Apple, and CNBC's Brian Schwartz discusses exclusive emails he received from Tesla CEO Elon Musk accusing President Biden of ignoring the EV giant. Monday.com Co-CEO Eran Zinman also joins as shares of the cloud platform slide on its Q4 results. Later, NASCAR President Steve Phelps breaks down the sport's expansion into gaming, simulated racing and more.

Dave co-founded the company that built the first - albeit not by much - ad server called AdKnowledge and later worked at BlueLithium, Yahoo and Drawbridge among othersMore

Dave co-founded the company that built the first - albeit not by much - ad server called AdKnowledge and later worked at BlueLithium, Yahoo and Drawbridge among othersMore

Today you'll hear me on the "Insights To Live By" podcast by Matt Zinman. We'll speak about insights to live by, seasons of renewal, coming back from rock bottom and the importance of having an action plan. Go Subscribe to "You Are Worthy" https://podcasts.apple.com/ca/podcast/insights-to-live-by/id1523879759?i=1000522285355 Connect With Natasha https://www.instagram.com/natashagrano/ https://www.natashagraziano.com/ Text Natasha +1 917 672 4905

How's your happierness? Yes, I had a double-take when I first read this word, but it makes perfect sense. Happierness – are you striving to make the most of every situation? Joining me today is Matt Zinman, to chat about what happierness is and how we can find it in our lives. Connect with Matt on MattZinman.com and on LinkedIn @mattzinman, Facebook @ZismsReaderForum, Instagram @matt.zinman and Twitter @MattZinman. Your support of The Roller Coaster is always appreciated, please make sure to SUBSCRIBE! If you REALLY like what you hear, leave a comment, and share it with your friends! You can find me on: www.therollercoaster.com Facebook @therollercoasterpodcast Instagram @the_roller_coaster_podcast JOIN US! www.necturegrowth.com and follow Necture Growth Network on Instagram @necturegrowth. Reach me at hello@necturegrowth.com. Thanks for joining me today and until next time I'm sending my virtually distant hugs!

Are you able to notice the changes in your mood, energy, outlook, etc. that happen before or at the beginning of your depressive episodes? Do you consider those warning signs an opportunity to better manage your mental health? In the second part of our conversation with Matt Zinman, he tells us about a 3-Day Rule that really works for him. He also shares other mental-health management tools he's created and shares. (links below) https://mattzinman.com/ Ps. I welcome you to add “DD100” to the show notes and the link MattZinman/LifeUpgrade That will provide a $100 Gift Code to your listeners who want to do the new course. I also have a 100% refund guarantee so it is risk-free.

Show date 8/26/2021

In this episode, Neena is joined by author and course creator, Matt Zinman. They talk about his book, Z-isms: Insight to Live By, and his courses that would help you get on the track to self-discovery, self-awareness, and self-kindness. Matt also shares how he got through the toughest of times in life, how he defeated depression, and how he made it his life goal to instill greater presence, passion, and purpose to help others live fully. Make sure you tune in to get the sweet deal Matt gives to anyone who listens to this podcast!   Matt is a difference-maker, optimist, author, podcast host, nonprofit founder, and well-being advocate devoted to personally enrich the ‘Happierness' of at least 100 million people by 2025. His book, “Z-isms: Insights to Live By” is based on his experiences as an entrepreneur, athlete, single parent, caregiver, and nonprofit founder.    He is also the host of "Insights to Live By," a podcast that invites guests to share their own life lessons. Matt has also created online courses, including the Mindset Reset and his comprehensive Life Upgrade.   Learn more about Matt and how to upgrade your life: Website: https://mattzinman.com/ Life Upgrade Course: https://mattzinman.com/lifeupgrade/ Insights To Live By Matt Zinman: https://podcasts.apple.com/us/podcast/insights-to-live-by/id1523879759 Get his book Z-isms: https://mattzinman.com/z-isms/    Social accounts: Facebook: https://www.facebook.com/ZismsInsightsToLiveBy IG: https://www.instagram.com/matt.zinman/ LinkedIn: https://www.linkedin.com/in/mattzinman/   Show notes [2:02] Who is Matt Zinman [6:56] What is Z-isms? [11:16] Diving deeper into the Life Upgrade [17:36] What you get out of the course [25:48] On energy management [28:04] How does Matt get through the tough times? [31:35] Needing to face the past in order to move forward [35:52] Discount code for Straight Talk listeners: StraightTalk100 [44:07] Outro   We discuss real-life topics, tools, and tips on how to challenge and transform your thinking with no sugar added. Hope you will go on the journey with us as we grow, fail, and get back up.  https://linktr.ee/Neenaperez

This week's guest, Matt Zinman, has a unique and deep understanding of life with a mental-health challenge. He not only had his own depression, but was impacted by other members of his family who lived with their own. In the first of a 2-part interview, Matt shares about his mental-health journey. Next week, he'll share some fabulous tools and self-care techniques he's learned along the way. https://mattzinman.com/

'I come from a non-profit mentality and asking for the sale can feel awkward and disingenuous, but at the same time, I know I'm bringing value and people are going to seek out and fulfill that value for the things you create. But more specifically, at its very core, wealth is about freedom. It is about maintaining my freedom in my life, over my time, over my energy, and managing my days more aligned with energy than time. Money is my friend, and difference making is my spend.' ~ Matt Zinman You can learn more about Matt here >> https://mattzinman.com/ Join Joy Kingsborough, myself, and a community of Conscious Creators who are intentionally raising their vibe together, connecting with soul-aligned friends, and collaborating for global change! To learn more visit: https://www.facebook.com/groups/mindshiftcreators/ Would you like to learn more about numerology? To learn more visit: https://www.joyandjonah.com/quantum-numerology

Matt Zinman is a difference-maker devoted to personally enrich the lives of at least 100 million people by 2025. His new book, “Z-isms: Insights to Live By” is based on his experiences as an entrepreneur, athlete, single parent, caregiver and nonprofit founder. He is also the host of "Insights to Live By," a podcast that invites guests to share their own life lessons. In addition, Matt is CEO of The Internship Institute, which he established in 2007 to "Make Experience Matter."

This week on the podcast I had the pleasure of chatting with Matt Zinman, the author of Z-ISMS and an advocate for male mental health. We chat about clubhouse, about mental health, as well as Matts journey to finding happiness and what it means to him after this last year. If you want to check out some of the resources he offers or courses he is putting together please check out his website https://mattzinman.com

Today we’re chatting with the host of Insights to Live By about making positivity a reflect, leaning toward optimism, earned confidence, staying grounded, self-belief, winning the battle within, AND inevitability thinking (along with a number of other topics). http://www.shatterthemoldpodcast.com

Welcome to the Lion's Den! This week, I had the chance to sit down with Mark Zinman, CPA, CITP, managing partner of Zinman & Company PC, and candidate for Newtown District Judge. Tune in to hear why Mark is running for Judge and how he plans to use his decades of experience as an accounting professional to balance the scales for the families and businesses throughout the Bucks County community.

Monday.com wasn't always worth billions. Its Co-Founders, Roy Mann and Eran Zinman share the top 5 things they'd repeat and the 5 they wish they'd done differently.

How Interns Can Be The Key to Growing Your Business.......Our guest on this episode is Matthew Zinman. Matt is founder of The Internship Institute to help employers make experience matter. Matt is also the author of Z-isms and the host of fast growing ‘Insights to Live By’ podcast. Find out more about Matt Zinman: Websites: https://mattzinman.com and z-isms.com Social Media: https://www.facebook.com/matthew.zinman/https://www.linkedin.com/in/mattzinman/ InstaGram https://www.instagram.com/matthewzinman/.......To find out how you can hire Dov Baron as a speaker or strategist for your organization:  DovBaron.com You can also join in the conversation here: https://tinyurl.com/F500Podcast Get bonus content on Patreon See acast.com/privacy for privacy and opt-out information.

As a business owner, bringing on an intern often sounds enticing. But interns are only as good as the framework that you have built in place for them. What's that? You don't have a strategy plan for your interns? Today's guest can help. He founded Internship Institute, helping businesses maximize the value of interns. Additionally, this athlete, single parent, caretaker, consultant and nonprofit founder has a goal of positively impacting 100,000,000 people in the next five years. Will you be one of them? Please welcome Matt Zinman. Contact Info https://z-isms.com https://mattzinman.com  

In this podcast im joined by Matthew Zinman Matt is host of Insights to live by Podcast and author of Z-isms - Linkedin: https://www.linkedin.com/in/mattzinman Instagram: @mathewzinman - Instagram: @Parrsitivity94 Email: theparrsitivitypodcast@gmail.com All my content/landing page: https://aw194dee.aweb.page/p/d0062c2e-0bba-44ab-8b08-17721144a4ec Twitter: @AdamparrL YouTube: The Parrsitivity Podcast https://m.youtube.com/channel/UCiHEKzkYjhvHaJWNj_Pc1Ag Donations: https://www.paypal.com/paypalme/Parrpodebay94 Patreon: https://www.patreon.com/TheParrsitivity_Podcast I hope this podcast provides you Value! Support this podcast

In this podcast im joined by Matthew Zinman Matt is host of Insights to live by Podcast and author of Z-isms - Linkedin: https://www.linkedin.com/in/mattzinman Instagram: @mathewzinman - Instagram: @Parrsitivity94 Email: theparrsitivitypodcast@gmail.com All my content/landing page: https://aw194dee.aweb.page/p/d0062c2e-0bba-44ab-8b08-17721144a4ec Twitter: @AdamparrL YouTube: The Parrsitivity Podcast https://m.youtube.com/channel/UCiHEKzkYjhvHaJWNj_Pc1Ag Donations: https://www.paypal.com/paypalme/Parrpodebay94 Patreon: https://www.patreon.com/TheParrsitivity_Podcast I hope this podcast provides you Value! Support this podcast

Michael and Tom Zubal (The Book Brothers) veer from their usual path and bring on special guest renowned book collector Michael Zinman to set the record straight regarding and important 1990s rescue of tens of thousands of printed artifacts from the New York Public Library. Aside from sharing rare insight and first person experiences with The Brothers, Zinman appears in the recent film "The Booksellers"

Matt ZinmanLinkedIn:linkedin.com/in/mattzinmanWebsite:MattZinman.com  My social media links:Podcast:https://podcast.app/day-in-day-out-p832991Instagram:https://www.instagram.com/muui23LinkedIn page:https://www.linkedin.com/company/day-in-day-out-podcast/?viewAsMember=trueYouTube:https://bit.ly/2UVszCm

In this episode, Host Brenton Webber is joined by best-selling author, Matt Zinman. Join the two as they explore key insights to live by with the transformational economy in mind, developing and growing your interpersonal skills.  Driven by his devotion to positively impact others, Matt's aim is to personally enrich the lives of at least 100 million people by 2025. This intention coincides with the publishing of his book “Z-isms: Insights to Live By”, based on the guiding principles and pearls of wisdom each of us possesses that most often are at the heart of the advice we give others. -------Contact our guest - https://www.linkedin.com/in/mattzinman/ (https://www.linkedin.com/in/mattzinman/) http://mattzinman.com/ (http://mattzinman.com/) --- Contact our host - https://www.linkedin.com/in/brentonmwebber/ (https://www.linkedin.com/in/brentonmwebber/) https://www.halftimeorange.co.nz (https://www.halftimeorange.co.nz)

Matt Zinman | Podcast Host, Author, Entrepreneur & AthleteMatt Zinman is a difference-maker devoted to personally enrich the lives of at least 100 million people by 2025. His new book, Z-isms: Insights to Live By, is based on his experiences as an entrepreneur, athlete, single parent, caregiver and nonprofit founder. Matt is also the host of "Insights to Live By," a podcast that invites guests to share their own pearls of wisdom. He is also CEO of The Internship Institute, which he established in 2007 to "Make Experience Matter."Listen as Joseph and Matt provide "Insights To live By"... 

Matt Zinman is a personal success trainer whose varied experiences as an entrepreneur, athlete, single parent, caretaker, consultant, and nonprofit founder drive him to be a difference-maker. His earned insights about self-discovery, relationships, mindfulness, and life enrichment led Matt to write Z-isms: Insights to Live By and fulfill his goal to positively impact as many people as possible. In addition,, Matt is CEO of The Internship Institute which he established in 2007 to bridge the gap between education, active duty and employment by “Making Experience Matter.” Overall, Z-isms offers ways to better ourselves, our experiences and our encounters through self-discovery, purposeful relationships and heightened mindfulness, including with actionable tools and practices. Readers can also join a free private forum with a like-minded community dedicated to collective growth and better living as well as to interact more with me on a more personal level.Learn more at www.Z-isms.com Connect with Matt on Social MediaLinkedIn (primary): https://www.linkedin.com/in/mattzinman/ Facebook: https://www.facebook.com/ZismsInsightsToLiveBy Instagram: MatthewZinman Twitter: @MatthewZinman----------------------------------EXCITING NEWS!!! The Quantum SHIFT commUNITY is now online! Be a part of the high-vibe tribe at QuantumSHIFT.us and start your free ENViSiONEERING QuEST today! Support the show (http://quantumshift.us)

Hey there, Coach Curl here and welcome to the Today's Leader Podcast. We have had such a run of amazing guests and it's been an honour to interview them. Just between me and you, the line up continues into the future. I love the insights and advice that our guests offer willingly and I hope you do as well. Today I bring you a chat with Matt Zinman. It was energetic, it was a big light hearted at times, but Matt nails his purpose and message. Matt Zinman is a personal development trainer whose varied experiences as an entrepreneur, athlete, single parent, caretaker, consultant and nonprofit founder drive him to be a difference-maker and positively impact as many people as possible. Matt can be contacted through https://z-isms.com/In today's disruptive world, good leadership skills will always stand you in great stead. If you are looking to build better leadership skills, consider our sponsors. Think & Grow Business and the Coach Curl Academy.Think & Grow Business the home of the Think & Grow Business Mastermind, where we focus on personal, professional, and business growth. Check out thinkandgrowbusiness.com.auThe Coach Curl Academy has over 75 programs to help you build a better you. Join for just $1 for the first month. The Academy that equips you and enhances your mindset, leadership, and business. Check it out at thecoachcurlacademy.comYou are standing Stronger, Braver, and Wiser. Don't forget the golden rule – Don t be an A-Hole

Matt Zinman is a difference-maker devoted to personally enrich the lives of at least 100 million people by 2025. His new book, “Z-isms: Insights to Live By” is based on his experiences as an entrepreneur, athlete, single parent, caregiver and nonprofit founder. He is also the host of "Insights to Live By," a podcast that invites guests to share their own pearls of wisdom. In addition, Matt is CEO of The Internship Institute, which he established in 2007 to "Make Experience Matter." https://www.linkedin.com/in/mattzinman/ https://www.facebook.com/ZismsInsightsToLiveBy Website: https://mattzinman.com/ Website: https://www.internshipinstitute.org/

Matt Zinman is a difference-maker devoted to personally enrich the lives of at least 100 million people by 2025. His new book, “Z-isms: Insights to Live By” is based on his experiences as an entrepreneur, athlete, single parent, caregiver and nonprofit founder. He is also the host of "Insights to Live By," a podcast that invites guests to share their own pearls of wisdom. In addition, Matt is CEO of The Internship Institute, which he established in 2007 to "Make Experience Matter." https://www.linkedin.com/in/mattzinman/ https://www.facebook.com/ZismsInsightsToLiveBy Website: https://mattzinman.com/ Website: https://www.internshipinstitute.org/

Matt Zinman is a difference-maker devoted to personally enrich the lives of at least 100 million people by 2025. His new book, “Z-isms: Insights to Live By” is based on his experiences as an entrepreneur, athlete, single parent, caregiver and nonprofit founder. He is also the host of "Insights to Live By," a podcast that invites guests to share their own pearls of wisdom. In addition, Matt is CEO of The Internship Institute, which he established in 2007 to "Make Experience Matter." https://www.linkedin.com/in/mattzinman/ https://www.facebook.com/ZismsInsightsToLiveBy Website: https://mattzinman.com/ Website: https://www.internshipinstitute.org/

Speaking to the Experts About Loan PackagesTonight in The Lion's Den, we're getting down to the facts with financial experts Bob Christmas & Mark Zinman about loan packages and the impact they could have on small and mid-sized businesses.

With us today is Matt Zinman, author of the book, Z-isms: Insight to Live By. Matt  is a personal development trainer whose varied experiences as an entrepreneur,athlete, single parent, caretaker, consultant and nonprofit founder drive him to be a difference-maker- positively impacting people. His book - Z-isms- Insights to live By is richly authentic, deeply personal and highly motivating. Z-isms offers new ways to better ourselves, our experiences and out encounters. Its impossible to read Z-isms and not be better for it. We talk with Matt on this episode about Self discover- defeating worry and anxiety. Recognizing true perception. We will learn how to become more engaged in our personal interactions. Heightening our mindfulness while swimming with the current. And enriching our lives by winning the battles within on this episode of The Light Inside… --- Send in a voice message: https://anchor.fm/thelightinside/message

In Ep. 11 "Z-Isms" on The Grind 1.0, I sit down with Matt Zinman. We discuss great ways to approach difficult decisions in life. His "Z-Isms" mantra is a great spin on positive thinking backed by seamless execution. Now we all know, nothing is really seamless or positive at the moment. But hear me out on this episode. Matt makes a great case on why one should seek self development and stay in a mental zone that allows for some balance of productivity and happiness. You don't want to miss this episode, tune in to learn and take a peak into Matt's life. He just completed his new book "Z-Isms" If you want to reach out to Matt or purchase the book his website link is here. https://z-isms.com/ We hope you enjoy this episode of The Grind 1.0 as much as we did recording it. Until next time. Your Host Carl Dunn

On this episode, Candy interviews Matt Zinman. Matt Zinman is the author of “Z-isms: Insights to Live By” and a difference-maker driven to positively impact as many people as possible. The book is based on his experiences as an entrepreneur, athlete, single parent, caretaker and nonprofit founder. Matt is also the CEO of The Internship … Continue reading EP18: Interview with Matt Zinman →

Matt Zinman "Z-isms to Live By" on The Erica Glessing Show Podcast #5021 Ever optimistic and bright author Matt Zinman joins Erica today in this conversation about his book, his life's work, and how he stays positive even when life is being unpredictable. More About Matt Zinman Matthew Zinman founded the Internship Institute in 2007 to bridge the gap between education and employment with an aim to cultivate prosperity for students, veterans, organizations, communities and the economy overall. He began his own successful career in marketing communications as an intern. Working for some of Philadelphia's largest public relations agencies and as a consultant to nearly 100 companies, Mr. Zinman also has managed and mentored more than 200 college interns. An experiential learning activist for the past 15 years, he is a frequent lecturer at colleges, universities, professional associations and civic organizations and a published author on a number of related topics. Mr. Zinman earned his bachelor's degree at Temple University. Find out more: https://www.internshipinstitute.org/    

The guest this week on the Jewish Sacred Aging Podcast is Heshie Zinman, chair of the LGBT Elder Initiative in Philadelphia. The LGBT Elder Initiative  is committed to assuring that lesbian, gay, bisexual and transgender older adults have rights and opportunities to live vibrant, creative and mutually supportive lives. To achieve this vision, the mission of the LGBTEI is to foster and advocate for services, resources and institutions that are competent, culturally sensitive, inclusive and responsive to the needs of LGBT elders in the Delaware Valley and beyond. The LGBTEI is dedicated to building bridges between Aging and LGBT service and community organizations and consumers through advocacy, information, education and referral. [spp-player] About the Guest Heshie Zinman has a long history of activism on both the local and national level. He has a passionate commitment for the health and well-being of LGBT and HIV communities and helped shape the city's response to the HIV/AIDS epidemic from the period of 1987-1998. He was a driving force behind the start-up of Action AIDS, AIDS Fund, SafeGuards Gay Men's Health Project and Delaware Valley Legacy Fund. He founded the AIDS Library of Philadelphia (which today resides at Philadelphia FIGHT) and went on to become the Executive Director of the AIDS Information Network. Heshie has worked as HIV Community Relations Manager for Dupont Pharmaceuticals Company and Bristol-Myers Squibb Pharmaceuticals. He currently serves as board chair of the LGBT Elder Initiative. Heshie has served on many other boards of directors, most recently joining the board of Philadelphia Corporation For Aging and the Mayor's Commission on Aging. Born in Philadelphia, Heshie holds a BA degree from Penn State University and an MBA from St. Josephs University.